In addition to OAB, GLP-1 receptor agonists have gained interest across a spectrum of urologic conditions including erectile dysfunction, prostate cancer, male fertility, and urolithiasis [41,42,43,44,45,46,47,48,49]. Here, GLP1R is linked to prostate carcinoma.